Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis

[1] Jemal A(2011)Global cancer statistics CA Cancer J Clin. 61 69-90

[2] Bray F(2005)Global cancer statistics, 2002 CA Cancer J Clin. 55 74-108

[3] Center MM(2000)Endogenous estrogens as carcinogens through metabolic activation J Natl Cancer Inst Monogr. 27 67-73

[4] Ferlay J(2000)Estrogens as endogenous genotoxic agents–DNA adducts and mutations J Natl Cancer Inst Monogr. 27 75-93

[5] Ward E(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-717

[6] Forman D(2008)The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors Ann Oncol. 19 16-27

[7] Parkin DM(2011)Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update Breast Cancer (Dove Med Press). 3 113-25

[8] Bray F(2011)Aromatase, aromatase inhibitors, and breast cancer J Steroid Biochem Mol Biol. 125 13-22

[9] Ferlay J(2013)Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women Breast. 22 121-9

[10] Pisani P(2010)Meta-analysis of breast cancer outcomes inadjuvant trials of aromatase inhibitors versus tamoxifen J Clin Oncol. 28 509-18

[1] Jemal A(2011)Global cancer statistics CA Cancer J Clin. 61 69-90

[2] Bray F(2005)Global cancer statistics, 2002 CA Cancer J Clin. 55 74-108

[3] Center MM(2000)Endogenous estrogens as carcinogens through metabolic activation J Natl Cancer Inst Monogr. 27 67-73

[4] Ferlay J(2000)Estrogens as endogenous genotoxic agents–DNA adducts and mutations J Natl Cancer Inst Monogr. 27 75-93

[5] Ward E(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-717

[6] Forman D(2008)The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors Ann Oncol. 19 16-27

[7] Parkin DM(2011)Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update Breast Cancer (Dove Med Press). 3 113-25

[8] Bray F(2011)Aromatase, aromatase inhibitors, and breast cancer J Steroid Biochem Mol Biol. 125 13-22

[9] Ferlay J(2013)Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women Breast. 22 121-9

[10] Pisani P(2010)Meta-analysis of breast cancer outcomes inadjuvant trials of aromatase inhibitors versus tamoxifen J Clin Oncol. 28 509-18